Our results show that the CDK4 modification profile of thyroid tumors and cell lines can also be predicted using the expression values of the same 11 genes used to predict the CDK4 modification profiles of breast tumors (26), reaching accuracies of 98.2% in tumors and 90.5% in cell lines, with a binary A/nonA classification. This evidence concerns the gene CDK4 and breast neoplasm.